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Abstract
Background: Central giant-cell granuloma (CGCG) is a non-neoplastic benign bony 
lesion of unknown origin. However, genetic abnormalities, trauma, inflammation, and 
intrabony hemorrhage are likely causative factors. It occurs most frequently in young adults 
under 30 years of age; females are affected more frequently than males and the anterior part 
of the jaw and the mandible are the sites most affected. In radiography, it appears either as 
a unilocular or multilocular radiolucency. According to its biological characteristics, two 
variants exist: The aggressive variant shows rapid growth with pain, root resorption, tooth 
displacement, jaw expansion, and a tendency for recurrence ; the nonaggressive variant, is 
usually asymptomatic and slow growing. Aim: This study aims to highlight the advantages 
and disadvantages of the primary approaches to the treatment of CGCG through review of 
the existing literature. Conclusion: The different clinical behaviour of the lesions, that are 
difficult to distinguish histologically, lead to different treatment modalities ranging from 
radical resection to non-surgical therapy in the form of steroids, calcitonin, or interferon. 
Non-surgical therapy outcomes fail to achieve the surgery results in monitoring the lesions 
with restricted long-term follow-up. Most cases require further surgical intervention. 
Newer combination therapy is under investigation, using both surgical and the medical 
treatments to control the lesions. Although this is a rare bone tumor, controlled clinical 
studies with standardized procedures should be implemented to increase understanding. 
Clinical Significance: There is significant lack of agreement between the different 
treatment options (ranging from surgical to non-surgical). This is due to the diverse 
clinical behaviour of the lesion. Surgical treatment is widely accepted and regarded as the 
common treatment choice. However, it is also variable, with en bloc resection giving the 
most desirable outcome. Non-surgical options (corticosteroids, calcitonin, and interferon) 
have been applied and their valuable outcomes that must be considered.
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Introduction
Central giant-cell granuloma (CGCG) is an uncommon, 
benign, and aggressive intraosseous localized lesion that occurs 
within the jawbones. CGCG represents approximately 7% of 
all benign jaw tumors and was first described by Jaffe in 1953 as 
“an idiopathic, non-neoplastic, proliferative lesion.”[1] The World 
Health Organization defines CGCG as “an intraosseous lesion 
consisting of cellular fibrous tissue that contains multiple foci 
of hemorrhage, aggregation of multinucleated giant cells, and 
occasional trabeculae of woven bone.”[2-5]
The exact nature of CGCG is unknown and debatable. 
Suggested theories include a reactive lesion, developmental 
anomaly, or benign neoplasm. In addition, the etiology of the 
lesion is uncertain, despite the hypotheses defining it as an 
aggressive inflammatory process or neoplastic proliferation. 
Furthermore, local trauma, bleeding, and genetic abnormalities 
are also suggested as possible etiologies.[3,6,7]
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CGCG is one of the most common lesions that cause 
jaw expansion; it occurs with a frequency similar to various 
odontogenic cysts.[8] On physical examination, the lesion 
appears smooth surfaced with spongy to firm consistency.[9] 
It predominantly occurs in children or in young adults under 
30  years of age, with a clear predisposition toward females. It 
occurs twice as frequently in the mandible than the maxilla, with 
restriction to the tooth-bearing areas of the jaw. In the maxilla, it 
favors the anterior region, while in the mandible, it commonly 
occurs anterior to the first molar tooth and extends to cross the 
midline.[1,6,9]
CGCG usually occurs as a single lesion, although multiple 
lesions may arise in rare cases where they are associated with 
syndromes such as Noonan Syndrome, neurofibromatosis 
type 1, or even cherubism.[10]
Different biological characteristics may be observed clinically, 
classifying CGCG into non-aggressive and aggressive variants. 
The non-aggressive variant is a relatively symptomless, slow-
growing lesion that is usually discovered on routine radiograph. 
Conversely, the aggressive variant is commonly expansive with 
rapid growth producing pain, displacement of teeth and cortical 
perforation, and commonly recurs after removal.[1,11,12]
CGCG radiological appearance may be different, 
demonstrating unilocular or a multilocular radiolucency, 
with varying degrees of expansion of the cortical plates being 
reported.[11,12] Histological examination reveals multinucleated 
giant cells scattered within the fibroblastic stroma, with 
spindle-  and ovoid-shaped cells and extravasated red blood 
cells.[12]
Treatment options for CGCG include conservative 
treatment, curettage, excisional biopsy, and surgical resection. 
The recurrence rate of the aggressive lesions is generally 
high. Rare cases with spontaneous regression have also been 
reported.[3,5] Due to its variable clinical behaviors, choosing a 
treatment option is often problematic. Thus, the objective of this 
article is to provide thorough information through a review of 
treatment options, namely, surgery as primary treatment, and 
alternative modalities for managing CGCG.
Aggressive Versus Non-aggressive CGCG
In 1986, Choung et  al. classified CGCG as aggressive or non-
aggressive according to six criteria: Extension of the lesion, 
presence of pain, rapidity of growth, root resorption of associated 
teeth, cortical bone perforation, and recurrence after removal. 
Non-aggressive lesions are relatively asymptomatic and are 
usually discovered on routine X-ray. They are generally slow 
growing, painless and are less likely to displace teeth and tooth 
germs. Furthermore, they display an absence of resorbed roots, 
perforation of cortical bone, and low tendency of recurrence after 
surgical removal.[2,3,11,13,14]
In contrast, aggressive lesions have a rapid rate of growth and 
are usually large in size: Equal to or >5 cm in diameter. In addition 
to causing asymmetry of the face, pain and numbness, they are 
further characterized by tooth displacement, root resorption, 
cortical bone thinning or perforation, and a high recurrence rate 
after conservative surgical removal. De Lange and van den Akker 
noted that the aggressive type most commonly arises in younger 
age groups.[2,3,11]
Radiographic characteristics of CGCG are not 
pathognomonic. Lesions may appear as an ill-  or well-defined 
uni-  or multi-locular radiolucency. Large lesions usually show 
internal bony septa revealing the multiloculation of the lesion. 
A variable degree of cortical expansion and/or perforation, root 
resorption of adjacent teeth, displacement of adjacent teeth, and 
tooth germs has been described.[11,12,15]
Histopathological examination of CGCG demonstrates 
multinucleated giant cells disseminated haphazardly along 
with mononuclear proliferating fibroblasts contained by a 
collagenous stroma that may contain myxoid ground substance. 
Multinucleated cells appear relatively variable in size, shape, 
and number of nuclei; they may aggregate focally or be 
diffusely scattered through the lesion.[16] CGCG also encloses 
extravasated red blood cells, hemosiderin-laden macrophages 
and endothelial cell-lined vascular structures accompanying 
proliferating fibroblasts that bear a resemblance to granulation 
tissue. A variable amount of osteoid and newly formed bone may 
be noted within CGCG lesions.[5,17,18]
The CGCG diagnosis depends on the clinical and 
radiological features, biological characteristics of the lesion and 
histopathological appearance, which are distinct and easy to 
recognize.[19]
Aggressive and non-aggressive lesions are histologically similar; 
most authors report no significant difference between the two 
lesions. However, some authors reported that aggressive lesions 
are associated with large-sized multinucleated giant cells with an 
increased number of nuclei and large number of cells per fraction 
surface occupied, compared to the non-aggressive type.[2,5]
Treatment of CGCG
CGCG is a non-reparative expansible lesion. Untreated, it results 
in destruction of the adjacent tissues and leads to cortical bone 
perforation.[2] The nature of CGCG is uncertain. Common 
suggestions are that it is a reactive, self-curing, spontaneously-
regressing lesion, or a neoplastic aggressive type, which recurs 
after surgical removal. Recent studies accepted the two theories 
according to the different clinical behaviors and treatment 
response of CGCG variants.[5,19]
There is no conclusive distinction between the two variants 
of CGCG based on histopathological and immunohistochemical 
structures.[19] Consequently, responses to treatment and 
prognosis are difficult to predict. A recent study recommended 
immunohistochemical calcitonin and/or glucocorticoids 
(markers that stain receptors on mononuclear and multinuclear 
giant cells) as a relatively reliable and useful marker to be used 
planning treatment of CGCG lesions.[5,19] The options for 
treatment are surgical or non-surgical.
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Surgical Treatment
Surgical treatment options for CGCG vary significantly, ranging 
from simple curettage and enucleation to partial or total resection 
of the affected bone with safety margins. CT scans assist surgical 
treatment planning since they determine the size of the lesion, degree 
of cortical bone expansion, and extent of bone destruction.[3,15] 
Surgical treatment is usually the treatment of choice and is the 
conventional cure used in most cases. Selection of the best surgical 
procedure depends on many factors including biological behavior 
(aggressive versus non-aggressive), extent of the lesion, location, and 
radiological appearance. Conservative treatment with or without 
additional medical treatment or en bloc resection for aggressive 
lesions is a reported treatment strategy. After surgery, antibiotics, 
analgesics, and steroids are required along with monitoring of 
clinical and radiological parameters.[2,3,5,20-22]
According to different studies, recurrence rates may vary 
from 10% to 50% and are commonly associated with incomplete 
removal of the tumor. The most common treatment of CGCG 
is surgical curettage, which is associated with a 16–46% 
recurrence rate, especially in aggressive lesions and in younger 
male patients.[1,3,11,23] Previous studies reported no distinction 
in recurrence rates between the mandible and the maxilla when 
using curettage as a choice of treatment. This suggests that surgical 
curettage is not an efficient treatment of choice for CGCG.[2,10,23]
If recurrence occurs, then curettage, peripheral osteotomy, 
and bone resection need to be carried out. Some authors 
recommend managing safe surgical margins by microdrilling 
using diamond bur.[2]
In aggressive CGCG, conservative surgical treatment 
by means of curettage enhanced by peripheral osteotomy is 
associated with recurrence of the lesion. Bataineh et al. suggested 
an en bloc resection with 5 mm healthy tissue safety margin as the 
treatment of choice to offer maximum confidence.[2]
Radical surgery of large lesions may results in loss of teeth 
in young individuals, as well as disturbances in the function of 
the inferior alveolar nerve. Furthermore, esthetic and functional 
defects may occur. Curettage in fragile bones is difficult and 
presents a hazard to the growth centers of facial bones. These 
treatments essentially require reconstruction and rehabilitation 
using bone grafting for functional and esthetic defects, but 
the consequences result in a poor outcome in most cases.[1,9,11] 
Therefore, the suitability of radical surgical treatment is debatable 
when dealing with benign lesions like CGCG.[2]
Non-surgical Treatment
Recent studies have shifted toward non-surgical treatment of 
CGCG due to the high recurrence rate, tooth loss, defects, and 
morbidity associated with surgical treatment. In addition, results 
of varying success were obtained using alternative non-surgical 
treatments, which may decrease the need for major surgical 
techniques.[2,10]
Intralesional administration of corticosteroids, systemic 
calcitonin, and antiangiogenic drugs was targeted as 
pharmacological treatments of CGCG in many recent studies. 
The use of corticosteroids and calcitonin therapy is the result of 
the hypothesis that CGCG lesions are inflammatory in nature 
and that the giant cells possess osteoclastic characteristics. There 
is also an assumption that CGCG is a proliferative vascular 
lesion; hence, some studies reported a response to antiangiogenic 
therapy. Pharmacological treatments are reported to be effective 
in restricted clinical trials; however, the accessible long-term 
study data are limited. Radiotherapy has not been confirmed as a 
suitable alternative treatment, because irradiation may exacerbate 
malignancy when used to treat CGCG.[1,24]
Intralesional corticosteroid injection is one of the essential 
non-surgical management methods for CGCG and has been 
associated with successful results. The mechanism of action of 
corticosteroids has not been fully identified. In vitro studies of 
dexamethasone revealed that it acts on osteoclast precursors and 
encourages their proliferation and differentiation. Administration 
of intralesional corticosteroids into the bony cyst will result in 
fibrosis and reossification of the lesion due to inhibited secretion 
of lysosomal proteases, which inhibits osteoclasts and induces 
their apoptosis.[9,10]
Jacoway et al. first reported this treatment approach in 1988. 
An additional study conducted by Terry and Jacoway in 1994 
included four patients treated with steroids. A steroid injection 
was administered to all patients every week for 6  weeks. Three 
of the four patients showed confirmed complete resolution of 
CGCG, while one patient required further surgical treatment.[10] 
Limited studies reported promising results using intralesional 
corticosteroids as an unconventional treatment for CGCG. 
Marx and Stern used intralesional injections of corticosteroids 
and reported a complete resolution in 65% of cases. The 
remaining cases either failed to respond to treatment or recurred 
aggressively.[10]
Encouraging results were previously achieved using 
intralesional triamcinolone: 71.43% showed a good response 
(15 of 21  patients), 19.05% a moderate response (4 out of 
21 patients), and a negative response was observed in 9.52% (2 
of 21 patients).[25]
The advantages of corticosteroids are their low cost, ease of 
administration, and conservation of adjacent tissues, especially 
vital structures. Conversely, they are not suitable for patients 
suffering from diabetes, peptic ulcers, infections, and the 
immunocompromised or pregnant women. Furthermore, as the 
lesion resolves, drug administration becomes difficult and its 
effectiveness decreases hence. Furthermore, there are suggestions 
that steroids actually stimulate the growth of some lesions.[10,13,24]
Calcitonin is a 32 amino acid polypeptide hormone composed 
that is secreted by parafollicular cells (C cells). This hormone 
stimulates osteoblastic activity and decreases osteoclastic 
activity, resulting in a consequent reduction of calcium levels 
in the serum. Recent studies reveled that multinucleated 
giant cells in CGCG have similar osteoclastic characteristics. 
Calcitonin may limit the growth of CGCG through its effects 
on calcitonin receptors.[9,13] The mode of action of calcitonin is 
not fully understood. Some authors propose that calcitonin aids 
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in bone deposition and directly inhibits osteoclast activity, thus 
decreasing bone resorption.[11]
The biological efficiency of non-mammal calcitonin, such as 
salmon calcitonin, is superior to human calcitonin. Calcitonin 
is either administered through subcutaneous injection or nasal 
spray. The nasal spray dose is higher than subcutaneous injection 
due to the reduced absorption of the drug though the nasal 
route. Similar results were obtained using either delivery option. 
Most patients favor the nasal spray treatment to avoid daily 
injections.[13]
The first study to propose calcitonin use was introduced by 
Professor Harris in 1993 used calcitonin as an alternative surgical 
treatment for aggressive CGCG. Patients were injected with daily 
subcutaneous doses of calcitonin. De Lange et al., 1999, also used 
calcitonin effectively as a treatment of CGCG using nasal therapy 
and subcutaneous injections. The disadvantages reported for 
calcitonin include high cost, daily administration with long-term 
therapy, and side effects including nausea, vomiting, dizziness, 
and flushes.[11]
Interferon (IFN) is an antiangiogenic agent. Its use has 
been reported for various conditions such as hemangiomas and 
varying malignant tumors. IFN inhibits angiogenesis of lesions 
through inhibition of fibroblast growth factor. Recent studies 
postulate that CGCG is a proliferative vascular lesion, which may 
respond to antiangiogenic therapy. Furthermore, in vitro studies 
revealed that IFN aids bone deposition through stimulation of 
osteoblastic differentiation.[11,13,21]
Conclusion
Conservative surgical treatment is associated with a high 
recurrence rate, particularly in aggressive CGCG lesions. 
Conversely, radical surgical excision with safety margins is the 
best treatment for aggressive tumors but is associated with high 
morbidity. Non-surgical treatment demonstrates variable results, 
with limited cases and restricted long-term follow-up.
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